Radiofrequency Ablation of Small Thyroid Cancer–A Solution Looking for a Problem?
Menée en Chine sur la période 2014-2020 auprès de 1 613 patients atteints d'un carcinome papillaire de la thyroïde de stade T1N0M0, cette étude identifie des facteurs de risque de progression tumorale locale après une ablation par radiofréquence
Fortunately, most thyroid cancers are indolent and their treatment is de-escalating. What was once uniformly managed with total thyroidectomy, adjuvant radioactive iodine, and thyrotropin suppression is now individualized, involving less or even no surgery—for the right patients. Matching the right treatment to the right cancer biology for the right patient is fundamental to providing the best care. Discerning thyroid tumor biology, however, currently depends on characteristics of disease presentation (eg, extent) and pathologic information obtained after surgery. When considering innovative surgery-free treatment strategies, such as radiofrequency ablation (RFA), an intrinsic question remains: how, without surgery, can we obtain the best and most comprehensive information about thyroid tumor biology?
JAMA Surgery , éditorial, 2022